| Company Name | Fiscal Year | EPS (Actual) | EPS (Estimated) | Revenue (Actual) | Revenue (Estimated) | Exchange | |||
|---|---|---|---|---|---|---|---|---|---|
| Loading past events... | |||||||||
|
Tuesday - Jun 16, 2026 |
|||||||||
|
La-Z-Boy
LZB
|
Q4 FY26 | $1.26 | $0.82 | $570.34M | $569.23M |
NYSE |
|||
|
John Wiley & Sons
WLY
|
Q4 FY26 | $1.67 | $1.65 | $447.94M | $450M |
NYSE |
|||
|
Fathom Holdings
FTHM
|
Q1 FY26 | -$0.05 | -$0.05 | $93.70M | $93.70M |
NASDAQ |
|||
|
Vince Holding
VNCE
|
Q1 FY26 | -$0.16 | -$0.13 | $64.04M | $63.05M |
NASDAQ |
|||
|
ProPhase Labs
PRPH
|
Q4 FY25 | -$0.87 | -$1.20 | $784K | $9.67M |
NASDAQ |
|||
|
OFS Credit
OCCI
|
- | - | $0.19 | - | $9.20M |
NASDAQ |
|||
|
Sonoma Pharmaceuticals
SNOA
|
- | -$0.33 | -$0.24 | $5.56M | $5.57M |
NASDAQ |
|||
|
Anavex Life Sciences
AVXL
|
Q2 FY26 | -$0.07 | -$0.07 | - | - |
NASDAQ |
|||
